Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.61% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ADPT · Mar 31, 2024
Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-054604General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-91.59% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
11.23% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
31.74% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
56.89% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-116.45% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
72.23% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
34.15% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 6.28%
- Current
- 3.61%
- Delta
- -2.67%
- Previous
- -91.81%
- Current
- -91.59%
- Delta
- 0.21%
- Previous
- -8.11%
- Current
- 11.23%
- Delta
- 19.34%
- Previous
- 8.48%
- Current
- 31.74%
- Delta
- 23.26%
- Previous
- 55.63%
- Current
- 56.89%
- Delta
- 1.26%
- Previous
- -133.33%
- Current
- -116.45%
- Delta
- 16.88%
- Previous
- 71.72%
- Current
- 72.23%
- Delta
- 0.51%
- Previous
- 36.94%
- Current
- 34.15%
- Delta
- -2.80%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ADPT Fundamental State →Analogous To · ADPT state analogue 5 →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT CAPEX_INTENSITY_DECREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →Transitioned To · ADPT GROWTH_INCREASED →Transitioned To · ADPT INVENTORY_PRESSURE_INCREASED →Transitioned To · ADPT MARGIN_INCREASED →Transitioned To · ADPT PROFITABILITY_INCREASED →Transitioned To · ADPT R_AND_D_INTENSITY_INCREASED →Transitioned To · ADPT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.